Vol - 28, Issue - 04
About the Journal
[This article belongs to Volume - 28, Issue - 04]
International Medical Journal
Journal ID : IMJ-10-03-2021-791
Total View : 392

Abstract : Acquired aplastic anemia is a fatal disorder with a higher prevalence in Indian population compared to west. Eltrombopag combined with standard immunosuppressive therapy has shown improved response and survival with a reasonable safety. However, the studies exploring the response and safety in Indian setting is limited. Hence, this study evaluated the effectiveness and safety of eltrombopag, added to standard immunosuppression in Indian patients with acquired aplastic anemia. Patients (>5 years) of either sex with acquired aplastic anemia, who received eltrombopag in addition to standard immunosuppression with antithymocyte globulin/cyclosporine were included for this retrospective case record analysis. The complete, partial and overall hematologic response at 3 and 6 months were measured. Other outcomes evaluated in the study were survival and adverse events reported during 6 months of study period. Of 22 patients, both males and females were in equal proportion. The mean age was 35.1 years. Eleven (50%) patients had severe aplastic anemia, four had very severe aplastic anemia and seven patients had non-severe aplastic anemia. For newly diagnosed patients, the frontline use of eltrombopag with standard Immunosuppressive therapy at a dose of 100-150 mg/day for 6 months led to an overall response rate of 86.4% and a complete response of 31.8% at 6 months. Adverse effects included dyspepsia, and liver function derangement. Eltrombopag was well tolerated without significant side-effects mandating drug withdrawal. In a routine hematological clinical practice at an Indian Tertiary-Care setting, the use of eltrombopag in aplastic anemia patients is feasible, safe, and associated with favorable responses.

Our Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates